When can ADT be safely avoided with salvage radiation therapy?

Two randomized clinical trials (GETUG-AFU-16 and RTOG 9601) proved that adding at least some ADT to salvage radiation (SRT) improved outcomes. “Some ADT” was 6 months of goserelin acetate in the GETUG-AFU-16 trial, and 2 years of bicalutamide in the RTOG 9601 trial. … READ MORE …

Recovery of normal serum T levels after short-term ADT and radiation therapy

Two matters of concern to many prostate cancer patients who are considering radiation therapy as a treatment for their prostate cancer are : (a) Should I be having a short course of androgen deprivation therapy (ADT) along with the radiation therapy? (b) How well will I recover normal serum testosterone levels after such short-term treatment? … READ MORE …

Aggressive, neoadjuvant androgen ablation prior to surgery in higher risk prostate cancer patients

The development of drugs like abiraterone acetate and enzalutamide has stimulated new research into the use of such agents early on, in combination with first-line therapy, to see if it can affect the outcomes for men with high-risk and unfavorable intermediate-risk prostate cancer. … READ MORE …

Neoadjuvant ADT prior to radical surgery in high-risk prostate cancer patients

A group of South Korean researchers have just reported data on the prevalence and outcomes of pT0 disease after neoadjuvant androgen deprivation therapy (ADT) and radical prostatectomy among men receiving first-line therapy for high-risk prostate cancer. … READ MORE …

Androgen deprivation therapy and escalated dosing in radiation therapy

Several recent studies shed light on the optimal use of androgen deprivation therapy (ADT) used in conjunction with radiation therapy (RT), including new learnings about timing of ADT, RT dose, and their use in various risk categories. … READ MORE …

10-year data from RTOG 9910 endorses 8 weeks of neoadjuvant ADT prior to radiation

According to a report on Practice Update last Monday, some interesting data were presented at a plenary session at the annual meeting of the American Society for Radiation Oncology (ASTRO) based on 10-year follow-up of men in the RTOG 9910 trial. … READ MORE …

Radiation therapy, neoadjuvant ADT, and initial PSA response

New data from Zelefsky and his colleagues at Memorial Sloan-Kettering Cancer Center suggest that men who respond well to neoadjuvant androgen deprivation therapy (ADT) have better long-term outcomes after radiation therapy given with curative intent for localized prostate cancer. … READ MORE …

Over-use of neoadjuvant and concurrent ADT in combination with radiation therapy

As anyone who has had long-term androgen deprivation therapy is well aware, this type of treatment may be able to delay the onset or relieve the metastases and bone pain associated with progressive prostate cancer, but it is far from being benign — and comes with a wide spectrum of side effects that affect some patients very seriously. … READ MORE …

Abiraterone acetate may help to eliminate cancer prior to surgery in some men with high-risk, localized disease

According to the abstract of a paper to be presented at the upcoming meeting of the American Society for Clinical Oncology in Chicago at the beginning of June, 24 weeks of treatment with neoadjuvant abiraterone acetate + prednisone + an LHRH agonist appears to be able to eliminate visible risk of prostate cancer in post-surgical specimens in a small percentage of men diagnosed with high-risk disease. … READ MORE …

Adjuvant degarelix in combination with radiation therapy (instead of an LHRH agonist + an antiandrogen)

According to an announcement from the European Association for Urology (EAU) earlier today, data from a recently completed trial demonstrate that degarelix is “non-inferior” to the LHRH agonist goserelin acetate + the antiandrogen bicalutamide at reducing prostate volume in men with advanced hormone- dependent prostate cancer. … READ MORE …

Who needs aggressive treatment after initial radiation … and who does not?

A new report in Lancet Oncology offers guidance on which patients with prostate cancer who are initially treated with radiotherapy and 6 months of neoadjuvant androgen deprivation therapy (ADT) are at relatively high and relatively low levels of risk for prostate cancer-specific mortality. … READ MORE …

Results of RTOG 94-08 finally published in NEJM

As we first reported in March 2010, when data were originally presented at the Genitourinary Cancers Symposium, RTOG 94-08 has shown that 4 months of androgen deprivation therapy (ADT) before and during external beam radiation therapy (EBRT) reduces the overall and the prostate cancer-specific mortality rates for men with localized prostate cancer (clinical stages T1b, T1c, T2a, or T2b). … READ MORE …

6 months of neoadjuvant ADT doubles survival when given with radiation therapy

A new article in Lancet Oncology has reported that a mere 6 months of neoadjuvant hormone therapy, when combined with radiation therapy, cuts the risk of dying from locally advanced prostate cancer by 50 percent compared to radiation alone at 10 years of follow-up. … READ MORE …

Neoadjuvant hormone therapy for patients undergoing first-line radiation therapy

The Irish Clinical Oncology Research Group trial 97-01 was a randomized clinical trial designed to compare the long-term outcomes of patients treated with either 4 months or 8 months of hormonal therapy given before external beam radiotherapy for localized prostate cancer. … READ MORE …

Prostate cancer news report: Sunday, January 24, 2010

In this weekend’s prostate cancer news reports, we have addressed recent publications on:

  • A SNP that may be specifically linked to risk for prostate cancer in African Americans
  • The need for extended biopsies in men with larger prostates who are considering focal treatment for prostate cancer
  • A possible association between diabetes, race, obesity, and risk for prostate cancer progression
  • Neoadjuvant hormone therapy, brachytherapy, and all cause mortality in older patients … READ MORE …